After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
ApexOnco Front Page
Recent articles
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
First-in-human study listings include EOS-215 and RO7673396.
The company’s matching strategy for CB-010 will soon be put to the test.
Vobra-duo is discontinued at long last.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
While Sutro shows why it’s shelved luvelta-T.
